These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32536677)

  • 1. The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice.
    Yoshii N; Tochino Y; Fujioka M; Sakazaki H; Maruyama N; Asai K; Kakeya H; Shintaku H; Kawaguchi T
    Intern Med; 2020; 59(12):1509-1513. PubMed ID: 32536677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of baloxavir marboxil against influenza in children.
    Kakuya F; Haga S; Okubo H; Fujiyasu H; Kinebuchi T
    Pediatr Int; 2019 Jun; 61(6):616-618. PubMed ID: 31195429
    [No Abstract]   [Full Text] [Related]  

  • 3. Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons.
    Sun Y; Wagatsuma K; Saito R; Sato I; Kawashima T; Saito T; Shimada Y; Ono Y; Kakuya F; Minato M; Kodo N; Suzuki E; Kitano A; Chon I; Phyu WW; Li J; Watanabe H
    Antiviral Res; 2024 Aug; 228():105938. PubMed ID: 38897317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
    Harada N; Shibata W; Koh H; Takashita E; Fujisaki S; Okamura H; Nanno S; Yamada K; Nakamae H; Hino M; Kakeya H
    BMC Infect Dis; 2020 Jul; 20(1):478. PubMed ID: 32631240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
    Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients.
    Taieb V; Ikeoka H; Ma FF; Borkowska K; Aballéa S; Tone K; Hirotsu N
    Curr Med Res Opin; 2019 Aug; 35(8):1355-1364. PubMed ID: 30810054
    [No Abstract]   [Full Text] [Related]  

  • 7. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019.
    Takashita E; Kawakami C; Ogawa R; Morita H; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Ota A; Togashi H; Saito A; Mitamura K; Abe T; Ichikawa M; Yamazaki M; Watanabe S; Odagiri T
    Euro Surveill; 2019 Mar; 24(12):. PubMed ID: 30914078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.
    Watanabe A; Ishida T; Hirotsu N; Kawaguchi K; Ishibashi T; Shishido T; Sato C; Portsmouth S; Tsuchiya K; Uehara T
    Antiviral Res; 2019 Mar; 163():75-81. PubMed ID: 30684563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
    Ikematsu H; Hayden FG; Kawaguchi K; Kinoshita M; de Jong MD; Lee N; Takashima S; Noshi T; Tsuchiya K; Uehara T
    N Engl J Med; 2020 Jul; 383(4):309-320. PubMed ID: 32640124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022-2023 influenza season in Japan.
    Chon I; Wagatsuma K; Saito R; Tang JW; Isamu S; Suzuki E; Shirahige Y; Kawashima T; Minato M; Kodo N; Masaki H; Hamabata H; Yoshioka S; Ichikawa Y; Sun Y; Li J; Otoguto T; Watanabe H
    Antiviral Res; 2024 Sep; 229():105956. PubMed ID: 38969237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza.
    Yang T
    Ann Pharmacother; 2019 Jul; 53(7):754-759. PubMed ID: 30674196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019.
    Takashita E; Ichikawa M; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Sugawara H; Sato A; Akimoto M; Mitamura K; Abe T; Yamazaki M; Watanabe S; Hasegawa H; Odagiri T
    Emerg Infect Dis; 2019 Nov; 25(11):2108-2111. PubMed ID: 31436527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
    Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
    Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
    Uehara T; Hayden FG; Kawaguchi K; Omoto S; Hurt AC; De Jong MD; Hirotsu N; Sugaya N; Lee N; Baba K; Shishido T; Tsuchiya K; Portsmouth S; Kida H
    J Infect Dis; 2020 Jan; 221(3):346-355. PubMed ID: 31309975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective observational study of the treatment of a nosocomial infection caused by oseltamivir-resistant influenza virus A with baloxavir marboxil.
    Fujita M; Matsumoto H; Inafuku Y; Toyama J; Fujita J
    Respir Investig; 2020 Sep; 58(5):403-408. PubMed ID: 32605828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baloxavir heralds a new era in influenza virus biology.
    Kikuchi T; Watanabe A
    Respir Investig; 2019 Jan; 57(1):1-2. PubMed ID: 30396860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza.
    Koshimichi H; Tsuda Y; Ishibashi T; Wajima T
    J Pharm Sci; 2019 May; 108(5):1896-1904. PubMed ID: 30557562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka.
    Yoshi N; Tocino Y; Fujioka M; Kureya Y; Asai K; Kimura T; Shinataku H; Hirata K
    Osaka City Med J; 2016 Dec; 62(2):29-38. PubMed ID: 30550708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza.
    Locke SC; Splawn LM; Cho JC
    Drugs Today (Barc); 2019 Jun; 55(6):359-366. PubMed ID: 31250840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baloxavir Marboxil (Xofluza) for Influenza.
    Erlich DR
    Am Fam Physician; 2019 Dec; 100(12):776-777. PubMed ID: 31845775
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.